So in honor of every spell gone wrong, every mysterious bubbling flask, and every suspicious stew Snape definitely judged you ...

Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.

Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

In this series, ‘Genomics 101’, we go back to basics and explore some of the most important topics in genomics. In this blog, ...

Transposon said its oral small molecule TPN-101 has been selected for testing as part of the HEALEY ALS platform trial.

To preventthalassemiain babies, parents — especially those with a family history of the condition — can take several ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The wildlife crossing will allow animals to cross over one of the busiest roadways in the world that sees around 300,000 ...

A new study will explore how pine trees adapt to climate change, with Michigan State researchers aiming to identify and breed ...

Endogenous intracellular allosteric modulators of GPCRs remain largely unexplored, with limited binding and phenotype data available. This gap arises from the lack of robust computational methods for ...